Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 278 No 7439 p188
17 February 2007

This article
Reprint   Photocopy

PDF 90K, Acrobat Reader

Letters

• Community pharmacy (3)
• Pfizer proposals
• COPD
• Statins
• Complementary medicine
• NHS
• Physician-assisted suicide (3)
• Prescribing
• Northern Ireland
• Medicines recycling
• Retention fees
• Reciprocity


Letters to the Editor

COPD

Give COPD the priority it deserves

From Mr P. Jerram, MRPharmS, and Ms S. Kearney

Chronic obstructive pulmonary disease (COPD) is a major drain on NHS reaources. It was responsible for 1,152,023 bed days in England in 2005 (when these patients were the third largest group of bed users). It is currently the fourth biggest killer in the UK and it is predicted that by 2020 it will be third in the leading world-wide cause of death from chronic disease.

There are two key changes occurring in the NHS in England that make the management of COPD more important than ever before: payment by results (PBR) and practice-based commissioning (PBC). PBR is a new finance system for paying hospitals that was first introduced in England in 2003 and was greatly expanded in April 2006. It is important for primary care because it makes it possible for primary care trusts and GPs to disinvest from hospitals for the first time; if a patient is not admitted, the GP does not pay the hospital. Under the old financial system it was extremely difficult to do this.

PBC, where clusters of GP practices opt to hold the budget for prescribing and hospital care, was first introduced in April 2005 and now nearly 90 per cent of GP practices are involved. PBC is important because GP clusters that save money on their budgets can reinvest these savings into additional patient care.

The Health Care Commission report on COPD in June 2006 said that a good deal more could be done to diagnose and effectively treat COPD. Furthermore the Department of Health announced that it was commissioning a national service framework for COPD, although this is not due for publication until 2008.

We believe that now is the time to work with colleagues to ensure COPD is given the priority long since afforded to cardiovascular and mental illness and that PBR and PBC offer the levers to make this happen.

Paul Jerram
Head of Medicines Management
Sarah Kearney
Respiratory Nurse Specialist
Isle of Wight Primary Care Trust

Send your letter to The Editor

Previous Topic (Pfizer proposals)
Next Topic (Statins)

Back to Top


©The Pharmaceutical Journal